Issue
Copyright (c) 2022 Christian German Ospina Pérez, Ivan David Lozada Martínez, José Carlos Posada Viana, Bernarda Cuadrado Cano
This work is licensed under a Creative Commons Attribution 4.0 International License.
Factors associated with pancreatitis after endoscopic retrograted cholangiopancreatography: a single center's experience in the Colombian Caribbean
Corresponding Author(s) : Ivan David Lozada Martínez
Ciencia e Innovación en Salud,
2022
Abstract
Background: Currently, endoscopic retrograde cholangiopancreatography (ERCP) is one of the most useful studies in the therapeutic approach to pancreato-biliary diseases. However, being an invasive procedure, it carries a certain risk of complications, such as pancreatitis. In Latin America, there is a great lack of epidemiological research on factors associated with the development of post-ERCP pancreatitis. Methods: Retrospective, quantitative and analytical case-control research, where patients older than 18 years who had undergone ERCP between 2013-2018 were included. Controls were chosen in a 2:1 ratio, evaluating sociodemographic, clinical, paraclinical, surgical and post-surgical variables. Results: A total of 180 ERCPs were identified, 32 cases of post-ERCP pancreatitis were detected (17.8%), and 64 patients were taken as controls. In the sample, female sex, pre-surgical ASA grade I, and pre-surgical diagnosis of predominantly lithiasis prevailed. When assessing risk by crude OR, there was an association of post-ERCP pancreatitis with the presence of abdominal pain (OR 4.2; 95% CI 1.6-10.7), pancreatic pain (OR 3.2; 95% CI 2. 3-4.3), vomiting (OR 4.2; 95% CI 1.1-15.6), abdominal distension (OR 8.3, 95% CI 2.4-10.4), lipase > 948 IU/L (OR 8.3; 95% CI 2.4-10.4) and amylase greater than 350 IU/L (OR 1.4; 95% CI 5.0-20.4). Conclusions: Factors associated with post-ERCP pancreatitis were abdominal pain, pancreatic pain, vomiting, abdominal distension, elevated lipase and amylase
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-18.
- Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc. 2011; 73(2):275-82.
- Tsuchiya T, Itoi T, Sofuni A, Itokawa F, Kurihara T, Ishii K, et al. Temporary pancreatic stent to prevent post endoscopic retrograde cholangiopancreatography pancreatitis: a preliminary, single-center, randomized controlled trial. J Hepatobiliary Pancreat Surg 2007; 14:302-7.
- Lukić S, Alempijević T, Jovanović I, Popović D, Krstić M, Ugljesić M. Occurrence and risk factor for development of pancreatitis and asymptomatic hyperamylasemia following endoscopic retrograde cholangiopancreatography--our experiences. Acta Chir Iugosl. 2008; 55(1):17-24.
- Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004; 59:845-64.
- Cha SW, Leung WD, Lehman GA, Watkins JL, McHenry L, Fogel EL, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study. Gastrointest Endosc. 2013; 77(2):209-16.
- Mine T, Morizane T, Kawaguchi Y, Akashi R, Hanada K, Ito T, et al. Clinical practice guideline for post-ERCP pancreatitis. J Gastroenterol. 2017; 52(9):1013-1022.
- Hwang HJ, Guidi M, Curvale C, Lasa J, Matano R. Pancreatitis post-CPRE: ¿precorte temprano o prótesis pancreática?: ensayo aleatorizado, multicéntrico y análisis de costo-efectividad. Rev Esp Enferm Dig. 2017; 109(3):174-179.
- Murillo Zolezzi A, Vidal González P, Cárdenas Salomon C, Robles Castillo J, Sarue Saed N. Pancreatitis aguda severa temprana postcolangiopancreatografía retrógrada endoscópica, presentación de un caso. Cirugia Endoscopica. 2009; 10(1):40-44.
- Del Castillo Rangel FR, Arango Molano LA. Determinación de la frecuencia de hiperamilasemia y pancreatitis en pacientes llevados a colangiopancreatografía retrógrada endoscópica. Rev Col Gastroenterol. 2017; 32(3):223-229.
- Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383–93.
- Ministerio de Salud de Colombia. Resolución 8430 de 1993 [Internet]. [Consultado 28 Jun 2021]. Disponible en: https://www.minsalud.gov.co/salud/Lists/Normatividad%20%20Salud/DispForm.aspx?ID=2110&ContentTypeId=0x0100A08A4A1DF8E9D448BEF600BFAC0E7622
- Asociación Médica Mundial. Declaración de Helsinki de la AMM – principios éticos para las investigaciones médicas en seres humanos [Internet]. [Consultado 28 Jun 2021]. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
- Cevallos V. Sensibilidad y especificidad de la amilasemia como ayuda diagnóstica inicial para pancreatitis aguda en pacientes que acudieron por dolor abdominal agudo al servicio de emergencia del Hospital Vozandes – Quito entre los meses de julio del año 2006 y junio del año 2007. Rev Médica la Univ Costa Rica. 2009; 3(1):96–8.
- Herrera MF, Jácome GG, Llumipanta IE. Utilidad de amilasa y lipasa en diagnóstico y tratamiento de dolor abdominal agudo. Quim Cent. 2017; 6(01):11–9.
- Ojo AS. Pancreatic Duct Variations and the Risk of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Cureus. 2020; 12(9):e10445.
- Pekgöz M. Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment. World J Gastroenterol. 2019; 25(29):4019-4042.
- Maruyama H, Shiba M, Ishikawa-Kakiya Y, Kato K, Ominami M, Fukunaga S, et al. Positive correlation between pancreatic volume and post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2020; 35(5):769-776.
- Lyu Y, Cheng Y, Wang B, Xu Y, Du W. What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018; 18(1):106.
- Garg R, Mohan BP, Krishnamoorthi R, Rustagi T. Pre-endoscopic retrograde cholangiopancreatography (ERCP) administration of rectal indomethacin in unselected patients to reduce post-ERCP pancreatitis: A systematic review and meta-analysis. Indian J Gastroenterol. 2018; 37(2):120-126.
- Vadalà di Prampero SF, Faleschini G, Panic N, Bulajic M. Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis and systematic review. Eur J Gastroenterol Hepatol. 2016; 28(12):1415-1424.
- Zhou W, Li Y, Zhang Q, Li X, Meng W, Zhang L, et al. Risk factors for postendoscopic retrograde cholangiopancreatography pancreatitis: a retrospective analysis of 7,168 cases. Pancreatology. 2011; 11(4):399-405.
References
Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-18.
Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc. 2011; 73(2):275-82.
Tsuchiya T, Itoi T, Sofuni A, Itokawa F, Kurihara T, Ishii K, et al. Temporary pancreatic stent to prevent post endoscopic retrograde cholangiopancreatography pancreatitis: a preliminary, single-center, randomized controlled trial. J Hepatobiliary Pancreat Surg 2007; 14:302-7.
Lukić S, Alempijević T, Jovanović I, Popović D, Krstić M, Ugljesić M. Occurrence and risk factor for development of pancreatitis and asymptomatic hyperamylasemia following endoscopic retrograde cholangiopancreatography--our experiences. Acta Chir Iugosl. 2008; 55(1):17-24.
Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004; 59:845-64.
Cha SW, Leung WD, Lehman GA, Watkins JL, McHenry L, Fogel EL, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study. Gastrointest Endosc. 2013; 77(2):209-16.
Mine T, Morizane T, Kawaguchi Y, Akashi R, Hanada K, Ito T, et al. Clinical practice guideline for post-ERCP pancreatitis. J Gastroenterol. 2017; 52(9):1013-1022.
Hwang HJ, Guidi M, Curvale C, Lasa J, Matano R. Pancreatitis post-CPRE: ¿precorte temprano o prótesis pancreática?: ensayo aleatorizado, multicéntrico y análisis de costo-efectividad. Rev Esp Enferm Dig. 2017; 109(3):174-179.
Murillo Zolezzi A, Vidal González P, Cárdenas Salomon C, Robles Castillo J, Sarue Saed N. Pancreatitis aguda severa temprana postcolangiopancreatografía retrógrada endoscópica, presentación de un caso. Cirugia Endoscopica. 2009; 10(1):40-44.
Del Castillo Rangel FR, Arango Molano LA. Determinación de la frecuencia de hiperamilasemia y pancreatitis en pacientes llevados a colangiopancreatografía retrógrada endoscópica. Rev Col Gastroenterol. 2017; 32(3):223-229.
Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383–93.
Ministerio de Salud de Colombia. Resolución 8430 de 1993 [Internet]. [Consultado 28 Jun 2021]. Disponible en: https://www.minsalud.gov.co/salud/Lists/Normatividad%20%20Salud/DispForm.aspx?ID=2110&ContentTypeId=0x0100A08A4A1DF8E9D448BEF600BFAC0E7622
Asociación Médica Mundial. Declaración de Helsinki de la AMM – principios éticos para las investigaciones médicas en seres humanos [Internet]. [Consultado 28 Jun 2021]. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
Cevallos V. Sensibilidad y especificidad de la amilasemia como ayuda diagnóstica inicial para pancreatitis aguda en pacientes que acudieron por dolor abdominal agudo al servicio de emergencia del Hospital Vozandes – Quito entre los meses de julio del año 2006 y junio del año 2007. Rev Médica la Univ Costa Rica. 2009; 3(1):96–8.
Herrera MF, Jácome GG, Llumipanta IE. Utilidad de amilasa y lipasa en diagnóstico y tratamiento de dolor abdominal agudo. Quim Cent. 2017; 6(01):11–9.
Ojo AS. Pancreatic Duct Variations and the Risk of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Cureus. 2020; 12(9):e10445.
Pekgöz M. Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment. World J Gastroenterol. 2019; 25(29):4019-4042.
Maruyama H, Shiba M, Ishikawa-Kakiya Y, Kato K, Ominami M, Fukunaga S, et al. Positive correlation between pancreatic volume and post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2020; 35(5):769-776.
Lyu Y, Cheng Y, Wang B, Xu Y, Du W. What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018; 18(1):106.
Garg R, Mohan BP, Krishnamoorthi R, Rustagi T. Pre-endoscopic retrograde cholangiopancreatography (ERCP) administration of rectal indomethacin in unselected patients to reduce post-ERCP pancreatitis: A systematic review and meta-analysis. Indian J Gastroenterol. 2018; 37(2):120-126.
Vadalà di Prampero SF, Faleschini G, Panic N, Bulajic M. Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis and systematic review. Eur J Gastroenterol Hepatol. 2016; 28(12):1415-1424.
Zhou W, Li Y, Zhang Q, Li X, Meng W, Zhang L, et al. Risk factors for postendoscopic retrograde cholangiopancreatography pancreatitis: a retrospective analysis of 7,168 cases. Pancreatology. 2011; 11(4):399-405.